Breaking News Instant updates and real-time market news.

FB

Facebook

$182.64

-1.13 (-0.61%)

, OXY

Occidental Petroleum

$62.00

-0.35 (-0.56%)

08:55
04/25/19
04/25
08:55
04/25/19
08:55

Notable open interest changes for April 25th

Wednesday's total option volume of 17.9 million contracts resulted in net open interest growth of 3.08 million calls and 3.27 million puts. Facebook (FB), Occidental Petroleum (OXY), Microsoft (MSFT) and Tesla (TSLA) saw the greatest growth. Top five new positions opened include 45k Cenovus Energy (CVE) May-19 11 calls, 21k YPF (YPF) Jan-20 10 puts, 20k Amarin (AMRN) Jul-19 20 calls, 20k AK Steel (AKS) May-19 2.5 puts and 19k Anadarko (APC) May-19 72.5 calls.

FB

Facebook

$182.64

-1.13 (-0.61%)

OXY

Occidental Petroleum

$62.00

-0.35 (-0.56%)

MSFT

Microsoft

$125.00

-0.5 (-0.40%)

TSLA

Tesla

$258.70

-5.15 (-1.95%)

  • 28

    Apr

  • 06

    May

  • 10

    May

  • 29

    May

  • 30

    May

  • 03

    Jun

  • 03

    Jun

  • 08

    Jun

  • 10

    Jun

  • 23

    Jun

  • 06

    Aug

FB Facebook
$182.64

-1.13 (-0.61%)

04/25/19
JMPS
04/25/19
NO CHANGE
Target $220
JMPS
Outperform
Facebook price target raised to $220 from $195 at JMP Securities
JMP Securities analyst Ronald Josey reiterated his Outperform rating on Facebook and raised his price target on the stock to $220 from $195 after the company's Q1 report, which he said highlighted the company's size and scale across users and advertisers. While he thinks core Facebook and Instagram have "long runways," Josey said his key takeaway from the company's report and call was the focus on building a more private "living room" type platform. While this privacy push could impact Facebook's current businesses over time, he believes it could unlock newer opportunities around payments and messaging and attract a greater overall user base, Josey tells investors.
04/25/19
WEDB
04/25/19
NO CHANGE
Target $220
WEDB
Outperform
Facebook price target raised to $220 from $200 at Wedbush
Wedbush analyst Michael Pachter raised his price target for Facebook to $220 from $200 after the company delivered revenue upside relative to consensus expectations driven by audience and impressions growth. The analyst expects Facebook to continue its rapid growth overseas and to increase monetization of under-penetrated Instagram, WhatsApp, and Messenger. He reiterates an Outperform rating on the shares.
04/25/19
RHCO
04/25/19
NO CHANGE
Target $115
RHCO
Hold
PayPal price target raised to $115 from $88 at SunTrust
SunTrust analyst Andrew Jeffrey raised his price target on PayPal to $115, saying that while its Q1 results were "mixed" with in-line revenue and lower-than-expected adjusted EBIT, he believes investors are more focused on the company's "transformational drivers". The analyst points to PayPal's "Venmo monetization, recent MercadoLibre (MELI) investment, and its Instagram (FB) partnership." Jeffrey is keeping his Hold rating on PayPal shares however, noting that the risk/reward in its valuation is "balanced."
04/25/19
JEFF
04/25/19
NO CHANGE
Target $230
JEFF
Buy
Facebook price target raised to $230 from $200 at Jefferies
Jefferies analyst Brent Thill raised his price target for Facebook to $230 from $200 saying last night's "beat quarter" proves the company can sustainably grow its organic business while also investing for longer term initiatives. Facebook surprised with lower than anticipated operating expenditure growth of 39%, says the analyst, whose initial estimate was 50%. Better than expected marketing spend and lower than expected hiring contributed to the beat and should also help with lower than anticipated expense growth throughout 2019, Thill tells investors in a post-earnings research note titled "Better Friend Than You Thought." He sees upside in 2019 and 2020 from Instagram through better Stories monetization and new initiatives in commerce. The analyst keeps a Buy rating on Facebook.
OXY Occidental Petroleum
$62.00

-0.35 (-0.56%)

04/24/19
JPMS
04/24/19
NO CHANGE
Target $74
JPMS
Neutral
Occidental's raised offer for Anadarko 'not entirely surprising,' says JPMorgan
Occidental Petroleum (OXY) made a $76 per share offer this morning for Anadarko (APC), which is "not entirely surprising," JPMorgan analyst Phil Gresh tells investors in a research note, adding that the new tidbits were the magnitude of synergies that Occidental proposed, which was materially higher than Chevron's (CVX), and Occidental's corresponding asset sale plan of $10B-15B. Gresh believes the merits of this transaction hinge entirely on the execution of the large synergy number being proposed, but also says he would not be surprised if Chevron raised its $65 per share bid for Anadarko and correspondingly raised its synergy target. The analyst maintains a Neutral rating and $74 price target on Occidental Petroleum.
04/25/19
ATLE
04/25/19
DOWNGRADE
ATLE
Neutral
Occidental Petroleum downgraded to Neutral from Overweight at Atlantic Equities
04/25/19
MSCO
04/25/19
NO CHANGE
MSCO
Strategic value of Occidental bid less clear than Chevron's, says Morgan Stanley
Morgan Stanley analyst Devin McDermott estimated that Occidental's (OXY) cash and stock bid for Anadarko (APC) implies about $73 per share, net of the breakup fee and yesterday's move in the share price of Occidental, which is roughly a 16% premium to Chevron's (CVX) previously accepted offer. However, Occidental's proposal comes with higher risk as it relies on asset sales for funding, requires a vote by Occidental's shareholders and carries more integration risk, the analyst tells investors. He continues to believe that a deal with Chevron represents a better potential strategic combination, citing his view that Chevron would ultimately be able to extract more synergies from a transaction than Occidental. If Chevron hypothetically matched Occidental's terms, the deal accretion would still be strong and leverage would stay low, said McDermott, who noted that he has no knowledge of any intention by Chevron to increase its bid.
04/25/19
JEFF
04/25/19
DOWNGRADE
Target $79
JEFF
Hold
Jefferies downgrades Anadarko to Hold, sees limited upside from here
Jefferies analyst Mark Lear downgraded Anadarko Petroleum (APC) to Hold from Buy with an unchanged price target of $78. Occidental Petroleum (OXY) yesterday confirmed weeks of speculation that a superior bid for Anadarko had been disregarded in favor of Chevron's (CVX) $65 per share offer, Lear tells investors in a research note. The analyst says that while he awaits Anadarko's response to the hostile bid, he believes Occidental's offer better recognizes the value of the company's underlying assets. Lear thinks it is possible that Chevron could come back with a slightly higher bid. However, he sees limited upside potential to Anadarko shares at this point.
MSFT Microsoft
$125.00

-0.5 (-0.40%)

04/25/19
KEYB
04/25/19
NO CHANGE
Target $143
KEYB
Overweight
KeyBanc remains bullish on Microsoft, raises price target to $143
KeyBanc analyst Brent Bracelin reiterates an Overweight rating on Microsoft, while raising his price target on the shares to $143 from $141 on a multiyear model transformation driven by fast-growing cloud and digital segments that are sustaining high growth at scale. The analyst notes that commercial cloud grew 41% year over year despite approaching a $40B run-rate scale, with the "strong" revenue beat for Q3 driven by strength in server and Windows products that was accentuated by the continuation of robust cloud adoption.
04/25/19
JPMS
04/25/19
NO CHANGE
Target $145
JPMS
Overweight
Microsoft price target raised to $145 from $125 at JPMorgan
JPMorgan analyst Mark Murphy raised his price target for Microsoft to $145 from $125 following last night's fiscal Q3 results. Investor focus should be squarely on Microsoft's "sustainable, long-term share gains and double-digit growth outlook," Murphy tells investors in a post-earnings research note. He reiterates an Overweight rating on the shares.
04/25/19
BMOC
04/25/19
NO CHANGE
Target $147
BMOC
Outperform
Microsoft price target raised to $147 from $125 at BMO Capital
BMO Capital analyst Keith Bachman raised his price target on Microsoft to $147 and kept his Outperform rating after its Q3 earnings beat, saying the stock "can move higher" in spite of its recently expanded multiple. The analyst says the latest quarter further highlights the "durability" of Microsoft's business model, adding that the company also has "upside tension" relative to its June quarter guidance.
04/25/19
WEDB
04/25/19
NO CHANGE
Target $155
WEDB
Outperform
Microsoft price target raised to $155 from $150 at Wedbush
Wedbush analyst Daniel Ives raised his price target for Microsoft (MSFT) to $155 from $150 as he sees March results as "another feather in the cap for Nadella in the company's quest to become a cloud behemoth," with Azure growing 73% year over year and continuing to gain share versus the likes of AWS and Amazon (AMZN). Ives is bullish on Microsoft into the rest of 2019/2020 given his thesis that Azure's cloud momentum is still in its early days of playing out with the company's massive installed base, Office 365 transition on consumer/enterprise providing growth tailwinds for the next 12-18 months at least, and newer integrated product initiatives around consumers and cloud services are still playing out. He reiterates an Outperform rating on the shares.
TSLA Tesla
$258.70

-5.15 (-1.95%)

04/25/19
04/25/19
DOWNGRADE
Target $275

Neutral
Tesla downgraded to Neutral at Wedbush on 'loss of confidence in story'
As previously reported, Wedbush analyst Daniel Ives downgraded Tesla to Neutral from Outperform as the demand story is quickly changing and the company has "unfortunately not adjusted to an evolving EV landscape." The analyst views this quarter as "one of top debacles" he has ever seen while "Musk & Co. in an episode out of the Twilight Zone act as if demand and profitability will magically return to the Tesla story." Ultimately, Ives believes the company's guidance is aggressive and management/board is not taking aggressive enough cost cutting actions and shutting down future endeavors to preserve capital and give a sustained path to profitability for the Street. The analyst also lowered his price target on the shares to $275 from $365 to reflect his reduced numbers for the coming years and his loss of confidence in the story.
04/25/19
BOFA
04/25/19
NO CHANGE
Target $225
BOFA
Underperform
BofA says Tesla seems 'amenable' to capital raise after uglier than expected Q1
BofA Merrill Lynch analyst John Murphy said Tesla's "uglier than expected" Q1 results were largely due on an operating basis to weaker deliveries, lower pricing, and lighter gross margins and he revised his estimates to be relatively consistent with the company's outlook and commentary, though he keeps an Underperform rating and $225 price target on the shares. Murphy also said he sees an earnings/cash inflection in the second half as "somewhat questionable." He believes that Elon Musk now "appears amenable" to a capital raise, quoting the CEO as having said "At this point, I do think there is some merit to raising capital." Murphy noted that he does not expect Tesla to turn the corner on free cash flow until after 2020.
04/25/19
JMPS
04/25/19
NO CHANGE
Target $369
JMPS
Outperform
Tesla U.S. demand should recover over course of year, says JMP Securities
JMP Securities analyst Joseph Osha said Tesla's Q1 results were weak, but not more than he expected, and noted that its Q2 outlook was ahead of his previous estimates. The analyst, who thinks following the report that it is "clear that U.S. demand should recover over the course of 2019," believes the company can make money and is an attractive investment if Tesla can hit its volume targets. He lowered his price target on Tesla shares to $369 from $374 but maintains an Outperform rating on the stock.
04/25/19
JEFF
04/25/19
NO CHANGE
Target $400
JEFF
Buy
Jefferies still sees 'path to sustained profitability' for Tesla
Jefferies analyst Philippe Houchois says that beyond last night's headline miss and "ongoing stress," he saw "enough positive surprises from auto gross margin resilience, cash earnings and gross liquidity to argue the shares have sufficiently re-priced." The analyst, who admits his Tesla call is "hard to live with at times," still sees value in the company's electric vehicle/connectivity technology and experimentation. He remains confident "there is a path to sustained profitability." Houchois keeps a Buy rating on Tesla with a $400 price target.

TODAY'S FREE FLY STORIES

T

AT&T

$32.36

0.06 (0.19%)

, CMCSA

Comcast

$42.31

0.62 (1.49%)

17:58
06/16/19
06/16
17:58
06/16/19
17:58
On The Fly
Box Office Battle: 'Men in Black: International' wins weekend with just $28.5M »

Sony’s (SNE) "Men in…

T

AT&T

$32.36

0.06 (0.19%)

CMCSA

Comcast

$42.31

0.62 (1.49%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$51.42

1.735 (3.49%)

LGF.A

Lionsgate

$12.22

-0.85 (-6.50%)

DIS

Disney

$141.64

-0.09 (-0.06%)

VIAB

Viacom

$29.38

-0.28 (-0.94%)

VIA

Viacom

$34.61

0.14 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 24

    Jul

  • 25

    Jul

  • 08

    Aug

  • 08

    Aug

GS

Goldman Sachs

$191.71

0.24 (0.13%)

17:43
06/16/19
06/16
17:43
06/16/19
17:43
Periodicals
Goldman Sachs combining private-investing units, WSJ reports »

Goldman Sachs is pulling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 16

    Jul

DB

Deutsche Bank

$6.79

-0.07 (-1.02%)

17:38
06/16/19
06/16
17:38
06/16/19
17:38
Periodicals
Deutsche Bank to set up EUR50B bad bank, Financial Times reports »

Deutsche Bank is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$87.10

(0.00%)

16:35
06/16/19
06/16
16:35
06/16/19
16:35
Periodicals
Tires blow on United jet during Newark airport landing, Reuters reports »

Tires on a United…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$87.83

-0.48 (-0.54%)

16:33
06/16/19
06/16
16:33
06/16/19
16:33
Periodicals
Target registers back online after outage blamed on tech issue, Reuters says »

Target said its payment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$46.18

-0.54 (-1.16%)

16:30
06/16/19
06/16
16:30
06/16/19
16:30
Hot Stocks
Intel announces program for Israeli startups targeting tech inflections »

Intel announced a program…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 25

    Jul

BA

Boeing

$347.19

-1.54 (-0.44%)

16:27
06/16/19
06/16
16:27
06/16/19
16:27
Periodicals
Boeing says will take time to rebuild customer confidence, Reuters reports »

The head of Boeing said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 09

    Jul

GS

Goldman Sachs

$191.71

0.24 (0.13%)

16:19
06/16/19
06/16
16:19
06/16/19
16:19
Periodicals
Goldman Sachs skeptical of 'insurance' rate cuts from Fed, Reuters says »

Goldman Sachs economists…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 16

    Jul

BA

Boeing

$347.19

-1.54 (-0.44%)

16:16
06/16/19
06/16
16:16
06/16/19
16:16
Periodicals
Trials nearing for Boeing 737 Max fix, WSJ reports »

The Federal Aviation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 09

    Jul

ESLT

Elbit Systems

$154.55

0.55 (0.36%)

13:41
06/16/19
06/16
13:41
06/16/19
13:41
Hot Stocks
Elbit Systems awarded $50M contract »

Elbit Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$176.09

-0.74 (-0.42%)

13:40
06/16/19
06/16
13:40
06/16/19
13:40
Hot Stocks
Amgen announces BLINCYTO five-year overall survival data »

Amgen announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Sep

SILK

Silk Road Medical

$44.80

-0.95 (-2.08%)

13:35
06/16/19
06/16
13:35
06/16/19
13:35
Hot Stocks
Silk Road Medical announces final results for ROADSTER-2 study »

Silk Road Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

  • 26

    Aug

EDIT

Editas Medicine

$21.72

-0.78 (-3.47%)

13:30
06/16/19
06/16
13:30
06/16/19
13:30
Hot Stocks
Editas presents pre-clinical data in Sickle Cell Disease, Beta-Thalassemia »

Editas Medicine announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNSS

Sunesis

$0.90

-0.055 (-5.79%)

13:28
06/16/19
06/16
13:28
06/16/19
13:28
Hot Stocks
Sunesis announces preliminary data from Phase 1b/2 trial of Vecabrutinib »

Sunesis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

APLS

Apellis

$21.22

-0.14 (-0.66%)

13:23
06/16/19
06/16
13:23
06/16/19
13:23
Hot Stocks
Apellis presents data from ongoing Phase 2 PLAUDIT study of APL-2 »

Apellis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

FTSV

Forty Seven

$10.55

-0.02 (-0.19%)

13:16
06/16/19
06/16
13:16
06/16/19
13:16
Hot Stocks
Forty Seven announces data from Phase 1b/2 trial of 5F9 in combo with Rituximab »

Forty Seven announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$39.68

-0.23 (-0.58%)

13:06
06/16/19
06/16
13:06
06/16/19
13:06
Hot Stocks
AstraZeneca announces results from interim analysis of Phase 2 ASCEND trial »

AstraZeneca announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

STRO

Sutro Biopharma

$11.17

-0.34 (-2.95%)

13:02
06/16/19
06/16
13:02
06/16/19
13:02
Hot Stocks
Sutro Biopharma announces interim Phase 1 safety data for STRO-001 »

Sutro Biopharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BPMC

Blueprint Medicines

$90.65

-0.35 (-0.38%)

12:59
06/16/19
06/16
12:59
06/16/19
12:59
Hot Stocks
Blueprint Medicines presents updated EXPLORER trial data for Avapritinib »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

INCY

Incyte

$77.76

1.385 (1.81%)

12:52
06/16/19
06/16
12:52
06/16/19
12:52
Hot Stocks
Incyte announced results from Phase 2 study of Ruxolitinib cream in vitiligo »

Incyte announces 24-week…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

, INCY

Incyte

$77.76

1.385 (1.81%)

04:55
06/16/19
06/16
04:55
06/16/19
04:55
Conference/Events
European Hematology Association to hold a conference »

24th EHA Congress 2019…

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

INCY

Incyte

$77.76

1.385 (1.81%)

ARQL

ArQule

$8.17

1.88 (29.89%)

AMGN

Amgen

$176.09

-0.74 (-0.42%)

ALXN

Alexion

$117.94

0.65 (0.55%)

AGIO

Agios Pharmaceuticals

$47.97

-1.78 (-3.58%)

AZN

AstraZeneca

$39.68

-0.23 (-0.58%)

BLUE

Bluebird Bio

$117.57

-6.33 (-5.11%)

BMY

Bristol-Myers

$47.57

0.25 (0.53%)

CELG

Celgene

$96.49

0.07 (0.07%)

NVS

Novartis

$89.52

-0.07 (-0.08%)

NSTG

NanoString

$25.96

0.45 (1.76%)

KPTI

Karyopharm

$5.71

-0.04 (-0.70%)

JAZZ

Jazz Pharmaceuticals

$130.43

0.28 (0.22%)

GSK

GlaxoSmithKline

$40.12

0.015 (0.04%)

GILD

Gilead

$66.38

-0.62 (-0.93%)

DSNKY

Daiichi Sankyo

$0.00

(0.00%)

PFE

Pfizer

$42.75

0.24 (0.56%)

PTLA

Portola Pharmaceuticals

$25.78

-0.31 (-1.19%)

QGEN

Qiagen

$39.52

-0.07 (-0.18%)

RHHBY

Roche

$0.00

(0.00%)

RIGL

Rigel Pharmaceuticals

$2.06

-0.06 (-2.83%)

SNY

Sanofi

$42.46

-0.225 (-0.53%)

SGEN

Seattle Genetics

$68.67

-0.33 (-0.48%)

STML

Stemline

$14.20

0.12 (0.85%)

VSTM

Verastem

$1.39

0.125 (9.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 18

    Jun

  • 20

    Jun

  • 20

    Jun

  • 20

    Jun

  • 21

    Jun

  • 23

    Jun

  • 25

    Jun

  • 25

    Jun

  • 26

    Jun

  • 26

    Jun

  • 27

    Jun

  • 27

    Jun

  • 27

    Jun

  • 28

    Jun

  • 28

    Jun

  • 06

    Jul

  • 25

    Jul

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 26

    Aug

  • 28

    Aug

  • 29

    Aug

  • 02

    Sep

  • 03

    Sep

  • 16

    Sep

  • 04

    Nov

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

, GRUB

GrubHub

$70.15

-2.76 (-3.79%)

13:28
06/15/19
06/15
13:28
06/15/19
13:28
Periodicals
Amazon exit gives GrubHub stock boost, Barron's says »

Amazon (AMZN) is…

AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

GRUB

GrubHub

$70.15

-2.76 (-3.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

  • 10

    Jul

ABC

AmerisourceBergen

$85.01

-1.46 (-1.69%)

, CAH

Cardinal Health

$44.16

-1.13 (-2.50%)

13:20
06/15/19
06/15
13:20
06/15/19
13:20
Periodicals
McKesson, Cardinal Health looking like bargains, Barron's says »

Investors have halved the…

ABC

AmerisourceBergen

$85.01

-1.46 (-1.69%)

CAH

Cardinal Health

$44.16

-1.13 (-2.50%)

MCK

McKesson

$133.19

-1.7 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

RTN

Raytheon

$177.38

0.195 (0.11%)

, UTX

United Technologies

$125.30

0.45 (0.36%)

13:09
06/15/19
06/15
13:09
06/15/19
13:09
Periodicals
United Technologies, Raytheon stocks looking cheap, Barron's says »

Shares of United…

RTN

Raytheon

$177.38

0.195 (0.11%)

UTX

United Technologies

$125.30

0.45 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 17

    Jun

  • 17

    Jun

GRUB

GrubHub

$70.15

-2.76 (-3.79%)

, AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

13:04
06/15/19
06/15
13:04
06/15/19
13:04
Periodicals
Food fight extending well beyond restaurant delivery, Barron's says »

Amazon (AMZN) is quitting…

GRUB

GrubHub

$70.15

-2.76 (-3.79%)

AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

  • 10

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.